MDedge Cardiocast

ISCHEMIA trial hailed as practice changing The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves. DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics Further analyses from the DAPA-HF trial showed dapagliflozin cut death and heart failure events in HFrEF patients with no diabetes. Colchicine cut post-

Vascepa approved for cardiovascular risk reduction The FDA’s decision on cutting events in high-risk patients was based primarily on the REDUCE-IT trial. ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding Novel oral anticoagulants may be preferred over warfarin in patients with diabetes and AFib. HHS drug importation proposals aim to address high cos

Women have fewer cardiovascular events after non–ST-segment elevation ACS But they also remain undertreated with guideline-directed therapies. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * FDA panel rejects vernakalant bid for AFib cardioversion indication Eleven years after the first a

Icosapent ethyl cost effective in REDUCE-IT analysis Treatment with the fish-derived drug Vascepa for CV event reduction is more effective and less costly than placebo. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * DAPA-HF: Dapagliflozin benefits regardless of age, HF severity The SGLT2 i

This week’s Cardiocast is devoted entirely to Card Talk with cardiologist brothers Jim and Jerry Dwyer. They welcome two structural interventionalists at the Structural Heart and Valve Center at Emory Healthcare, Kendra J. Grubb, MD, and Isida Byku, MD. Both followed a unique track, training in both cardiac surgery and interventional cardiology and practicing in the fast-moving

In this special meeting edition of the Cardiocast, MDedge Cardiology editor Catherine Hackett is joined by MDedge reporters Mitchel L. Zoler, Bruce Jancin, and Richard Mark Kirkner. The MDedge cardiology team reviews three big stories from the 2019 annual scientific sessions of the American Heart Association in Philadelphia. * * * Help us make this podcast better! Please take th

ISCHEMIA trial hailed as practice changing The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics Further analy

Getting high heightens stroke, arrhythmia risks Cannabis use or abuse among the young was associated with adverse cardiovascular consequences in two studies. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * Bempedoic acid cuts LDL by 15% in patients with high levels despite maximal treatment

Closing the missing link between childhood risk factors and adult cardiovascular outcomes Prescient childhood cohort studies launched in the 1970s are paying off. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * Metabolic signs of adult diabetes apparent in very young children Disturbed HDL c

Patients frequently drive too soon after ICD implantation Many patients didn’t recall ever receiving instruction about when to drive again. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * One-third of CVD disease in blacks linked to hypertension A large analysis suggests intervention throug